Selumetinib (AZD6244) | Friends of Cancer Research

You are here

Selumetinib (AZD6244)

Sponsor: 
AstraZeneca Plc and Merck & Co., Inc.
Indication: 
Pediatric patients aged three years and older with neurofibromatosis type 1 (NF1) symptomatic and/or progressive, inoperable plexiform neurofibromas (PN)
Year: 
2019
Date: 
Apr 1st
FDA Status: 
Designation Granted